The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
IMPemBra, a phase 2 study comparing pembrolizumab with intermittent/short‐term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation: Three-year survival data and translational analyses.
 
Elisa A. Rozeman
No Relationships to Disclose
 
Judith M. Versluis
No Relationships to Disclose
 
Esmée P Hoefsmit
No Relationships to Disclose
 
Petros Dimitriadis
No Relationships to Disclose
 
Lindsay G. Grijpink-Ongering
No Relationships to Disclose
 
Karolina Sikorska
No Relationships to Disclose
 
Bart A. van de Wiel
Employment - BMSi
 
Birthe C Heeres
No Relationships to Disclose
 
Claudi Flohil
No Relationships to Disclose
 
Pia Kvistborg
No Relationships to Disclose
 
Daan van den Broek
Consulting or Advisory Role - Roche Molecular Diagnostics (Inst)
 
Annegien Broeks
No Relationships to Disclose
 
Jan Willem de Groot
Consulting or Advisory Role - Bristol-Myers Squibb; Pierre Fabre; SERVIER
 
Sofie Wilgenhof
No Relationships to Disclose
 
Marieke A. Vollebergh
No Relationships to Disclose
 
Johannes V. van Thienen
No Relationships to Disclose
 
John B. A. G. Haanen
Stock and Other Ownership Interests - Neogene Therapeutics
Consulting or Advisory Role - Achilles Therapeutics (Inst); bioNTech (Inst); Bristol-Myers Squibb (Inst); Immunocore (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Ipsen (Inst); Molecular Partners (Inst); MSD Oncology (Inst); Neogene Therapeutics; Novartis (Inst); Pfizer (Inst); POEM Health (Inst); Roche/Genentech (Inst); Sanofi (Inst); T-Knife (Inst); Third Rock Ventures (Inst)
Research Funding - Amgen (Inst); Asher Biotherapeutics (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Neon Therapeutics (Inst); Novartis (Inst)
 
Christian U. Blank
Stock and Other Ownership Interests - Immagene
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GenMab (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Third Rock Ventures
Research Funding - 4SC (Inst); Bristol-Myers Squibb (Inst); NanoString Technologies (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - WO 2021/177822 A1
Expert Testimony - Freshfields Bruckhaus Deringer
Travel, Accommodations, Expenses - Bristol-Myers Squibb